Lxbio inaugurates pioneering advanced therapies laboratory in Lisbon
21st April 2025
Lxbio has inaugurated the first laboratory in the Iberian Peninsula dedicated to the development of CAR-T cells and monoclonal antibodies, marking a major milestone for biotechnology in Portugal. Located at the Faculty of Pharmacy of the University of Lisbon, the new facility represents an initial investment of €4 million, with total investment expected to reach €20 million over the next three years.
The inauguration ceremony was attended by Portugal’s Minister of Health, Ana Paula Martins, who highlighted the strategic importance of science, innovation and biotechnology in strengthening the national healthcare system. She emphasized that this laboratory significantly enhances Portugal’s scientific and technological capacity, fostering closer collaboration between academia, industry and the State, while helping to attract talent and international investment.
The laboratory will operate as a Contract Research Organization (CRO), supporting pharmaceutical companies, start-ups and academic institutions in the transition from pre-clinical research to early clinical development. Its first international contract has already been signed with the Swiss company T-Oncology, underlining the project’s global appeal.
Specializing in cutting-edge therapies for oncological and immune diseases, the facility positions Lisbon as an emerging hub of excellence in biotechnology and places Portugal firmly on the European map for advanced therapeutic development.